Biotech

All Articles

Lykos will ask FDA to reconsider its own selection following turndown of MDMA treatment for post-traumatic stress disorder

.Observing an unsatisfactory showing for Lykos Rehabs' MDMA applicant for post-traumatic stress diso...

AN 2 halves head count, stops stage 3 test after data disappoint

.AN2 Therapies is reconsidering its service in response to lackluster midphase information, pledging...

Merck pays out $700M for bispecific, spying autoimmune opening and possibility to challenge Amgen in cancer cells

.Merck &amp Co. is actually paying out $700 thousand ahead of time to test Amgen in a blood cancer c...

Gilead pays out J&ampJ $320M to leave licensing bargain for seladelpar

.Along With Gilead Sciences about to an FDA choice for its liver illness drug seladelpar, the firm h...

' All palms on deck' at Lilly as peers target excessive weight market

.Chief executive officer David Ricks can see the providers putting together tents at basecamp behind...

Entero giving up staff, leaving office as well as stopping briefly R&ampD

.Bed mattress Liquidators has switched Entero Therapies white as a piece. The collector got Entero t...

Exelixis loses ADC after choosing it is actually no match for Tivdak

.Exelixis is giving up on its tissue aspect (TF)- targeting antibody-drug conjugate after ending the...

Relay loses interest in SHP2 inhibitor after Genentech leaves

.Three full weeks after Roche's Genentech unit bowed out an SHP2 prevention treaty, Relay Rehab has ...

Stoke's Dravet disorder med discharged of partial professional hold

.Stoke Therapeutics' Dravet disorder medication has been devoid of a partial grip, clearing the meth...

Fierce Biotech's Gabrielle Masson presents Strong 15 at NYSE

.Tough Biotech Partner Publisher Gabrielle Masson provided the 2024 lesson of Fierce 15 winners on t...